PhaseOne Trials
Hvidovre, 2650, Denmark
NCT Number: NCT00535639
This trial is performed to assess the tolerability of the ALK Tree Tablet in patients with birch pollen induced allergy
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Hvidovre, 2650, Denmark
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ALK-Abelló A/S
Industry
A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma).
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05476484
Allergic Rhinitis, Allergy
Hørsholm, Copenhagen, Denmark
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial DetailsNCT04322838
Allergy, Hypersensitivity
Tromsø, Norway
View Trial DetailsNCT02661074
Allergy, Anisakiasis
Boulogne-sur-Mer, France
View Trial Details